What If A.D.H.D. Isn’t About Attention at All?

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-29T09:17:12.028Z • Permanent link

Skeptical minds within the scientific community have long questioned the widely accepted notion that Attention Deficit Hyperactivity Disorder (ADHD) is primarily characterized by a lack of attention. A recent surge in research has led to a paradigm shift, suggesting that ADHD may not be about attention at all. Dr. Russell Barkley, a renowned psychologist and ADHD expert, has been at the forefront of this movement. His work has focused on the concept of sustained engagement, a key aspect of ADHD that has received relatively little attention in the past.

According to Dr. Barkley, sustained engagement refers to the ability to maintain focus over an extended period, even in the face of distractions. Individuals with ADHD often struggle with this aspect, leading to difficulties in completing tasks, following instructions, and maintaining relationships. However, the new research suggests that ADHD may be more closely linked to difficulties with executive functioning, working memory, and cognitive flexibility. This shift in understanding has significant implications for diagnosis, treatment, and management of the condition.

In 2020, the American Psychiatric Association released the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which includes a revised diagnostic criteria for ADHD. The revised criteria emphasize the importance of sustained attention, but also acknowledge that individuals with ADHD may exhibit a range of symptoms, including inattention, hyperactivity, and impulsivity. The new understanding of ADHD is also being reflected in the development of new treatments, such as cognitive-behavioral therapy (CBT) and medication, which target specific cognitive deficits rather than simply managing symptoms.

Companies such as Novartis and Eli Lilly are already beginning to capitalize on the shift in understanding of ADHD. Their new products, such as Vyvanse and Strattera, target specific cognitive deficits and are being marketed to healthcare professionals as a more nuanced approach to treatment. Research communities are also taking notice, with a growing number of studies exploring the cognitive and neural correlates of ADHD. The impact on markets is already being felt, with stocks such as Novartis and Eli Lilly experiencing significant gains in recent years.

The implications of this shift in understanding extend far beyond the realm of psychiatry, however. ADHD affects millions of people worldwide, including children, adults, and individuals with comorbid conditions. The impact on education, employment, and daily life is significant, with individuals with ADHD often facing barriers to success. By reframing the understanding of ADHD, we may be able to develop more effective treatments and strategies for improving outcomes. This, in turn, could have a profound impact on individuals, families, and society as a whole.

The shift in understanding of ADHD is not isolated to the field of psychiatry. Similar debates have been taking place in related fields, such as neuroscience and psychology. The concept of neurodiversity, which emerged in the 1990s, emphasizes the importance of accepting and valuing individual differences in brain function and behavior. This perspective has gained significant traction in recent years, with many researchers and clinicians beginning to question the notion of a single, "normal" brain. The ADHD debate is part of a larger conversation about the nature of human cognition and behavior.